Related Experiment Video

Updated: Dec 25, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K

Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor

Joseph Mikhael1, Kimberly R Noonan2, Beth Faiman3

  • 1Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center, Phoenix, AZ.

Clinical Lymphoma, Myeloma & Leukemia
|April 5, 2020
PubMed
Abstract

No abstract available in PubMed .

Keywords:
AdherenceRefractory multiple myelomaSide effect managementSupportive careSymptom management

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.8K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.4K

Related Experiment Videos

Last Updated: Dec 25, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.8K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K

Articles linked to this work by shared authors, journal, and citation graph.

Long-Term Progression-Free Survival in Patients Treated With RVD Induction and Risk-Adapted Maintenance.

Clinical lymphoma, myeloma & leukemia·2026

Survivorship and Health Maintenance in Patients With Multiple Myeloma: A Nurse-Led Survivorship Care Framework.

Clinical journal of oncology nursing·2026

African Genetic Similarity Is Associated with Reduced Inflammation and Enhanced Adaptive Immunity in Multiple Myeloma.

Blood·2026

Managing Novel CAR T-Cell Toxicities in Multiple Myeloma.

Cancer journal (Sudbury, Mass.)·2026

Redefining second-line treatment strategy, sequencing, and real-world implementation in relapsed/refractory multiple myeloma: insights from the 31st Annual Congress of the European Hematology Association.

Clinical advances in hematology & oncology : H&O·2026

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

Blood advances·2026

Clinical Characteristics and Prognostic Analysis of Pediatric Acute Myeloid Leukemia With CBFB::MYH11: A 10-Year Single-Center Cohort Study.

Clinical lymphoma, myeloma & leukemia·2026

Efficacy and Safety of Azacitidine in Patients With RUNX1::RUNX1T1 Measurable Residual Disease-Positive Acute Myeloid Leukemia After Consolidation Therapy Who Did Not Undergo Allogeneic Hematopoietic Stem-Cell Transplantation.

Clinical lymphoma, myeloma & leukemia·2026

Rituximab Versus Watchful Waiting for Asymptomatic Advanced-Stage Low-Tumor-Burden Follicular Lymphoma: A Systematic Review and Meta-Analysis.

Clinical lymphoma, myeloma & leukemia·2026

Infection Prevention and Management in Patients With Multiple Myeloma Treated With Bispecific Antibodies: A Case-Based Approach for Routine Clinical Practice.

Clinical lymphoma, myeloma & leukemia·2026

Changing Patterns of Causes of Death in Patients With Multiple Myeloma During the Modern Therapeutic Era.

Clinical lymphoma, myeloma & leukemia·2026

Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review.

Sexual medicine reviews·2026

Effect of abatacept on bone in patients with psoriatic arthritis-results from a prospective interventional high-resolution imaging study (ABEPSA).

EULAR rheumatology open·2026

Contemporary consensus and emerging directions in premature and delayed ejaculation: recommendations from the 5th International Consultation on Sexual Medicine.

Sexual medicine reviews·2026

Aldosterone synthase inhibitors may alter how primary care treats hypertension.

American journal of hypertension·2026

The hypertension specialist's perspective: aldosterone synthase inhibitors to fill the gap in difficult-to-control and resistant hypertension.

American journal of hypertension·2026

From bench to formulary: a pharmacological appraisal of aldosterone synthase inhibitors for uncontrolled and resistant hypertension.

American journal of hypertension·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us